, Singapore

Temasek buys minority stake in Irish drug tech startup Aerogen

Aerogen specialises in making and selling aerosol drug delivery systems.

Temasek has bought a minority stake in Irish drug delivery startup Aerogen through the purchase of a secondary share interest, an announcement revealed. 

In addition, Temasek’s managing director of investment Abhijeet Lele will join Aerogen’s board of directors following the close of the transaction.

Aerogen specialises in the design, manufacture and commercialisation of aerosol drug delivery systems and has an international presence with offices in UK, Germany, US, Middle East and Asia.

Aerogen’s patented vibrating mesh technology turns liquid medication into a fine particle mist which is then delivered to its patients’ lungs in an effort to enhance outcomes and give healthcare professionals a higher level of control and confidence, the statement said.

“We are excited to realise the growth opportunities this collaboration will bring,” Aerogen’s founder and CEO John Power said. “Temasek, our partner of choice, has deep global and sector expertise which will accelerate our market penetration.”

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.


If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.